{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:54:58Z","timestamp":1782276898257,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals"},{"name":"Onyx Pharmaceuticals, an Amgen subsidiary"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s12072-016-9774-x","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T12:18:01Z","timestamp":1480594681000},"page":"199-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma"],"prefix":"10.1007","volume":"11","author":[{"given":"Shi-Ming","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Tsung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Bin","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinn-Cherng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Tan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sien-Sing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Aude","family":"Le Berre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Grevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A. E.","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold","family":"Meinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"9774_CR1","unstructured":"The GLOBOCAN project. Lyon, France: International Agency for Research on Cancer, 2010. Available at: http:\/\/globocan.iarc.fr . Accessed 4 Nov 2015"},{"issue":"2","key":"9774_CR2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74\u2013108","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"9774_CR3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1008370324827","volume":"12","author":"SA Hussain","year":"2001","unstructured":"Hussain SA, Ferry DR, El-Gazzaz G, et al. Hepatocellular carcinoma. Ann Oncol. 2001;12(2):161\u2013172","journal-title":"Ann Oncol"},{"key":"9774_CR4","volume-title":"Hepatocellular carcinoma","author":"A Katherine","year":"2004","unstructured":"Katherine A, Hashem B. Global incidence of hepatocellular carcinoma. In: Bruix J, editor. Hepatocellular carcinoma. Barcelona: Permanyer; 2004"},{"issue":"1","key":"9774_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334","journal-title":"Lancet Oncol"},{"issue":"9399","key":"9774_CR6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907\u20131917","journal-title":"Lancet"},{"key":"9774_CR7","unstructured":"Prins K, Ploeger BA. Population pharmacokinetic analysis of sorafenib plasma concentrations in Phase II through Phase IV monotherapy studies. Bayer Internal Report R-8977; September 2013"},{"issue":"Suppl","key":"9774_CR8","first-page":"s23","volume":"41","author":"NH Prins","year":"2014","unstructured":"Prins NH, Grevel J, Mitchell D, et al. Population pharmacokinetics of sorafenib: a meta-analysis of patients with hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma [Abstract]. J Pharmacokinet Pharmacodyn. 2014;41(Suppl):s23","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"32","key":"9774_CR9","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","volume":"31","author":"AL Cheng","year":"2013","unstructured":"Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067\u20134075","journal-title":"J Clin Oncol"},{"issue":"28","key":"9774_CR10","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","volume":"31","author":"PJ Johnson","year":"2013","unstructured":"Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31(28):3517\u20133524","journal-title":"J Clin Oncol"},{"issue":"7","key":"9774_CR11","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1158\/1078-0432.CCR-11-2484","volume":"18","author":"CJ Peer","year":"2012","unstructured":"Peer CJ, Sissung TM, Kim A, et al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res. 2012;18(7):2099\u20132107","journal-title":"Clin Cancer Res"},{"issue":"10","key":"9774_CR12","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1634\/theoncologist.12-10-1178","volume":"12","author":"M Beldner","year":"2007","unstructured":"Beldner M, Jacobson M, Burges GE, et al. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist. 2007;12(10):1178\u20131182","journal-title":"Oncologist"},{"issue":"11","key":"9774_CR13","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","volume":"19","author":"ME Lacouture","year":"2008","unstructured":"Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19(11):1955\u20131961","journal-title":"Ann Oncol"},{"issue":"7","key":"9774_CR14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","volume":"6","author":"C Robert","year":"2005","unstructured":"Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491\u2013500","journal-title":"Lancet Oncol"},{"issue":"3","key":"9774_CR15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","volume":"158","author":"CH Yang","year":"2008","unstructured":"Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158(3):592\u2013596","journal-title":"Br J Dermatol"},{"issue":"4","key":"9774_CR16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2230.2011.04060.x","volume":"36","author":"L Zhang","year":"2011","unstructured":"Zhang L, Zhou Q, Ma L, Wu Z, Wang Y. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol. 2011;36(4):344\u2013350","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"9774_CR17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D36W96127D","volume":"17","author":"L Cuesta","year":"2011","unstructured":"Cuesta L, Betlloch I, Toledo F, Latorre N, Monteagudo A. Severe sorafenib-induced hand-foot skin reaction. Dermatol Online J. 2011;17(5):14","journal-title":"Dermatol Online J"},{"issue":"1","key":"9774_CR18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.suponc.2010.12.007","volume":"9","author":"E Manchen","year":"2011","unstructured":"Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol. 2011;9(1):13\u201323","journal-title":"J Support Oncol"},{"issue":"8","key":"9774_CR19","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","volume":"33","author":"Z Ren","year":"2015","unstructured":"Ren Z, Zhu K, Kang H, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(8):894\u2013900","journal-title":"J Clin Oncol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9774-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-016-9774-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9774-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T21:20:32Z","timestamp":1657920032000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-016-9774-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["9774"],"URL":"https:\/\/doi.org\/10.1007\/s12072-016-9774-x","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,1]]}}}